#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Clinical Oncology / 2021 - 3

COVID-19 and oncological disease

Czech version

Authors: Tomáš Šálek;  Ján Slopovský;  Štefan Pörsök;  Natália Pazderová;  Zuzana Mináriková;  Eva Zomborská;  Benjamin Špánik
Authors‘ workplace: Klinika klinickej onkológie, NOÚ, Bratislava, Slovenská republika
Published in: Klin Onkol 2021; 34(3): 211-219
Category: Review
doi: https://doi.org/10.48095/ccko2021211

Overview

Background: Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by the severe acute respiratory syndrome coronavirus named SARS-CoV-2, initially emerged in China in late 2019. The rapid global spread of this novel virus led the World Health Organization declare a pandemic with > 30,000,000 confirmed cases, 946,000 deaths and > 21,000,000 recoveries reported as of 18 September 2020, according to the Johns Hopkins Coronavirus Resource Center. Initial reports from Asia suggested that elderly patients with multiple comorbidities, specifically diabetes, hypertension, and obesity were at an increased risk of developing severe COVID-19 following a SARS-CoV-2 infection. As data on these risks have evolved, evidence has increasingly shown that patients with cancer are indeed a particularly vulnerable group. However, the effects of various confounding factors, including an older than average patient population who often have underlying comorbidities including a suppressed immune system and/ or a hypercoagulable state, have been difficult to separate from the effects of having cancer. Common presenting symptoms of SARS-CoV-2 including dyspnoea, cough, fever, fatigue, dysgeusia and, less commonly, diarrhoea and/ or a hyperinflammatory syndrome are equally confusing to clinicians as they all are common symptoms of both cancer and toxicity from anti-cancer therapy. Furthermore, the radiographic dilemma of distinguishing between immune-checkpoint inhibitor-induced pneumonitis from that caused by SARS-CoV-2 infection and conflicting data on the effects of certain therapies on patient outcomes has left clinicians with considerable angst on how to help patients with acute or worsening symptoms in an optimal way. Predicted increase in mortality follows not only from the delay in discovery and progress resulting from temporary closing of research laboratories at cancer centers but also from diversion of resources to patient care and temporary suspension of clinical trial enrolment both by companies and local institutions. The possibilities of travelling to specialized medical centers whose activities are essential for the delivery and improvement of patient care were reduced, too. Viral mutations might also occur during transmission and spread; this leads to a statement that SARS-CoV-2 will forever remain a looming threat to the oncological community. What is crucial to remember is that cancer itself is a pandemic with > 18,000,000 people dia­gnosed worldwide every year. Many societies, including the European Society for Medical Oncology and the American Society of Clinical Oncology, are providing clinical recommendations for the management of patients with cancer during this challenging time, recognizing that continuation in the precise treatment of our patients is critical for our role of physicians. Purpose: The aim of the presentation is to point out the contact or overlapping areas of both mentioned disease entities for the purpose of possible simplification of dia­gnostic and therapeutic management of a cancer patient with suspected or already proven  COVID-19 disease.

Keywords:

COVID-19 – cancer – CRP – White blood cells – coagulation – fever – recommendation

Sources
  1. Huang KJ, Su IJ, Theron M et al. An interferon- g-related cytokine storm in SARS patients. J Med Virol 2005; 75(2): 185–194. doi: 10.1002/ jmv.20255
  2. Wang Z, Yang B, Li Q et al. Clinical features of 69 cases with coronavirus disease 2019, Wuhan, China. Clin Infect Dis 2020; 71(15): 769–777. doi: 10.1093/ cid/ ciaa272.
  3. Deng Y, Liu W, Fang YY et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019, Wuhan, China: a retrospective study. Chin Med J 2020; 133(11): 1261–1267. doi: 10.1097/ CM9.0000000000000824.
  4. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340(6): 448–454. doi: 10.1056/ NEJM199902113400607.
  5. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062. doi: 10.1016/ S0140-6736(20)30566-3.
  6. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111(12): 1805–1812. doi: 10.1172/ JCI18921.
  7. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID--19) outbreak in China. JAMA 2020; 323(13): 1239. doi: 10.1001/ jama.2020.2648.
  8. Roxby AC, Greninger AL, Hatfield KM et al. Outbreak investigation of COVID-19 among residents and staff of an independent and assisted living community for older adults in Seattle, Washington. JAMA Intern Med 2020; 180(8): 1101–1105. doi: 10.1001/ jamainternmed.2020.2233.
  9. Auld SC, Caridi-Scheible M, Blum JM et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med 2020; 48(9): e799–e804. doi: 10.1097/ CCM.0000000000004457.
  10. Tang N, Li D, Wang X et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844–847. doi: 10.1111/ jth.14768.
  11. Zhang L, Yan X, Fan Q et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020; 18(6): 1324–1329. doi: 10.1111/ jth.14859.
  12. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis 2020; 95: 304–307. doi: 10.1016/ j.ijid.2020.04.061.
  13. Chen W, Zheng KI, Liu S et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbio­l Antimicrob 2020; 19(1): 18. doi: 10.1186/ s12941--020-00362-2.
  14. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999; 17(6): 1019–1025. doi: 10.1016/ s0736- -4679(99)00135-3.
  15. Bolayirli M, Turna H, Orhanoğlu T et al. C-reactive protein as an acute phase protein in cancer patients. Med Oncol 2007; 24(3): 338–344. doi: 10.1007/ s12032-007-0012-1.
  16. Allin KH , Nordestgaard BG. Elevated C-reactive protein in the dia­gnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 2011; 48(4): 155–170.doi: 10.3109/ 10408363.2011.599831.
  17. Yitang S, Jingqi Z, Kaixiong Y. White blood cells and severe COVID-19: a Mendelian randomization study. J Pers Med 2021; 11(3): 195. doi: 10.3390/ jpm11030195.
  18. Shoenfeld Y, Tal A, Berliner S et al. Leukocytosis in non hematological malignancies--a possible tumor-associated marker J Cancer Res Clin Oncol 1986; 111(1): 54–58. doi: 10.1007/ BF00402777.
  19. Fraissé M, Logre E , Pajot O et al.Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care 2020; 24(1): 275. doi: 10.1186/ s13054-020-03025-y.
  20. Kreuziger LB, Lee AY, Garcia D et al. COVID-19 and coagulopathy: frequently asked questions. [online]. Available from: https:/ / www.hematology.org/ covid-19/ covid-19-and-vte-anticoagulation.
  21. Iba T, Nisio MD, Levy JH et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017; 7: e017046. doi: 10.1136/ bmjopen-2017-017046.
  22. Thachil J, Tang N, Gando S et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 18(5): 1023–1026. doi: 10.1111/ jth.14810.
  23. Boccardi V, Ruggiero C, Mecocci P. COVID-19: a geriatric emergency. Geriatrics (Basel) 2020; 5(2): 24. doi: 10.1111/ jth.14810.
  24. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 23(11): 1061–1069. doi: 10.1001/ jama.2020.1585.
  25. International Society on Thrombosis and Haemostatis Guidelines. [online]. Available from: https:/ / www.isth.org/ page/ GuidanceDocuments.
  26. Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: bio­logical and clinical aspects J Thromb Haemost 2013; 11(2): 223–233. doi: 10.1111/ jth.12075.
  27. Preston T, Slater C, McMillan DC et al. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response J Nutr 1998; 128(8): 1355–1360. doi: 10.1093/ jn/ 128.8.1355.
  28. Sporn JR, Rickles FR. Coagulation abnormalities in cancer patients: clinical relevance. Chest 1994; 105(6): 1639. doi: 10.1378/ chest.105.6.1639.
  29. Ryan M, Levy MM. Clinical review: fever in intensive care unit patients. Crit Care 2003; 7(3): 221. doi: 10.1186/ cc1879.
  30. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol 2015; 15(6): 335–349. doi: 10.1038/ nri3843.
  31. Guan W-J, NiZ-Y, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720. doi: 10.1056/ NEJMoa2002032.
  32. Chen J, Qi T, Liu L et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infec 2020: 80(5):  e1–e6. doi: 10.1016/ j.jinf.2020.03.004.
  33. Zhong N, Zheng B, Li Y et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong. People’s Republic of China, in February, 2003. Lancet 2003; 362(9393): 1353–1358. doi: 10.1016/ s0140- -6736(03)14630-2.
  34. Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361(9371): 1767–1772. doi: 10.1016/ s0140--6736(03)13412-5.
  35. Choi WS, Kang C-I, Kim Y et al. Korean society of infectious D. Clinical presentation and outcomes of middle east respiratory syndrome in the Republic of Korea. Infect Chemother 2016; 48(2): 118–126. doi: 10.3947/ ic.2016.48.2.118.
  36. Lau SKP, Woo PC, Yip CC et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbio­l 2006; 44(6): 2063–2071. doi: 10.1128/ JCM.02614-05.
  37. Lai CC, Shih TP, Ko WC et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924. doi: 10.1016/ j.ijantimicag.2020.105924.
  38. O’Shea TJ, Cryan PM, Cunningham AA et al. Bat flight and zoonotic viruses. Emerg Infect Dis 2014; 20(5): 741–745. doi: 10.3201/ eid2005.130539.
  39. Schmidt J, Rasmussen JA . The influence of environmental temperature on the course of experimental herpes simplex infection. J Infect Dis 1960; 107: 356–360 doi: 10.1093/ infdis/ 107.3.356.
  40. Lwoff A. Factors influencing the evolution of viral diseases at the cellular level and in the organism. Bacteriol Rev 1959; 23(3): 109–124.
  41. Walker DL, Boring WD. Factors influencing host-virus interactions: III. Further studies on the alteration of coxsackie virus infection in adult mice by environmental temperature. J Immunol 1958; 80(1): 39–44.
  42. Bell J, Moore G. Effects of high ambient temperature on various stages of rabies virus infection in mice. Infect Immun 1974; 10(3): 510–515. doi: 10.1128/ IAI.10.3.510-515.1974.
  43. Toms GL, Davies JA, Woodward CG et al. The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence. Br J Exp Pathol 1977; 58(4): 444–458.
  44. Earn DJ, Andrews PW, Bolker BM. Population-level effects of suppressing fever. Proc Biol Sci 2014; 281(1778): 20132570. doi: 10.1098/ rspb.2013.2570.
  45. Graham NM, Burrell CJ, Douglas RM et al. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J Infect Dis 1990; 162(6): 1277–1282. doi: 10.1093/ infdis/ 162.6.1277.
  46. DoranTF, Angelis CD, Baumgardner RA et al. Acetaminophen: more harm than good for chickenpox? J Pediatr 1989; 114(6): 1045–1048 doi: 10.1016/ s0022- -3476(89)80461-5.
  47. Cai Y, Huang T, Liu X et al. The effects of” Fangcang, Huoshenshan, and Leishenshan” makeshift hospitals and temperature on the mortality of COVID-19. Peer J 2020; 8: e9578. doi: 10.7717/ peerj.9578.
  48. Wu C, Chen X, Cai Y et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934. doi: 10.1001/ jamainternmed.2020.0994.
  49. Johnson M. Neoplastic fever. Palliat Med 1996; 10(3): 217–224. doi: 10.1177/ 026921639601000306.
  50. Ogawara D, Fukuda M, Ueno S et al. Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Support Care Cancer 2016; 24(2): 615–619. doi: 10.1007/ s00520-015-2820-8.
  51. Schattner A, Keshet N. Pel–Ebstein cyclic fever: not just lymphoma. Am J Med 2010; 123(7): e3. doi: 10.1016/ j.amjmed.2009.12.030.
  52. Marinella MA. Fever in patients with cancer, infectious disease and antimicrobial agents. [online]. Available from: http:/ / www.antimicrobe.org/ e13.asp.
  53. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. [online]. Available from: https:/ / www.nejm.org/ doi/ full/ 10.1056/ nejmoa2002032.
  54. Miyashita H, Mikami T, Chopra N et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020; 31(8): 1088–1089. doi: 10.1016/ j.annonc.2020.04.006.
  55. Mehta V, Goel S, Kabarriti R et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020; 10(7): 935–941. doi: 10.1158/ 2159-8290.CD-20-0516.
  56. COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12–March 16, 2020. [online]. Available from: https:/ / www.cdc.gov/ mmwr/ volumes/ 69/ wr/ mm6912e2.htm.
  57. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–1069. doi: 10.1001/ jama.2020.1585.
  58. Richardson S, Hirsch JS, Narasimhan M et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323(20): 2052–2059. doi: 10.1001/ jama.2020.6775.
  59. Zukin M, Barrios CH, Pereira JR et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31(23): 2849–2853. doi: 10.1200/ JCO.2012.48.1911.
  60. Macarulla T, Pazo-Cid R, Guillén-Ponce C et al. Phase I/ II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2. J Clin Oncol 2019; 37(3): 230–238. doi: 10.1200/ JCO.18.00089.
  61. Smith JC, Sheltzer JM. Cigarette smoke triggers the expansion of a subpopulation of respiratory epithelial cells that express the SARS-CoV-2 receptor ACE2. [online]. Available from: https:/ / www.bio­rxiv.org/ content/ 10.1101/ 2020.03.28.013672v1.
  62. Vaduganathan M, Vardeny O, Michel T et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020; 382(17): 1653–1659. doi: 10.1056/ NEJMsr2005760.
  63. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1953–1966. doi: 10.1056/ NEJMoa030781.
  64. Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271–280. doi: 10.1016/ j.cell.2020.02. 052.
  65. Lin B, Ferguson C, White JT et al. Prostate-localized and androgenregulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59(17):  4180–4184.
  66. Afar DE, Vivanco I, Hubert RS et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res 2001; 61(4): 1686–1692.
  67. Stopsack KH, Mucci LA, Antonarakis ES, et al. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov 2020 [in press]. doi: 10.1158/ 2159-8290.CD-20-0451.
  68. COVID-19 and cancer. [online]. Available from: https:/ / www.esmo.org/ covid-19-and-cancer.
  69. West HJ. Italian oncologist offers cautionary advice on COVID-19 for US Centers: ‚I can tell you that it‘s really frightening‘. [online]. Available from: https:/ / www.medscape.com/ viewarticle/ 927213.
  70. Brar G, Pinheiro LC, Schusterman M et al. COVID-19 severity and outcomes in patients with cancer: a matched cohort study. J Clin Oncol 2020; 38(33): 3914–3924 doi: 10.1200/ JCO.20.01580.
Labels
Paediatric clinical oncology Surgery Clinical oncology
Léčba nemetastatického kastračně rezistentního karcinomu prostaty
Social factors influence the course and prognosis of malignat diseases
Current treatment of non-metastatic castration-refractory prostate cancer
Indications for venous access in oncology – recommendations of national professional societies and current state in the Czech Republic
Mechanobiology of cancerogenesis
Epithelioid hemangioendothelioma on PET/CT scan
The use of PET/ CT with a hypoxia marker (18F-MISO) in radiotherapy treatment planning
Lipozomální irinotekan – nová možnost systémové léčby karcinomu pankreatu
Genetic and epigenetic bases of prostate tumor cell radioresistance
Aktuality z odborného tisku
Životné jubileum doc. MU Dr. Juraja Kaušitza, CSc.
Jubileum prvej dámy radiačnej onkológie na Slovensku – MUDr. Eva Siracká, DrSc.
Article was published in

Clinical Oncology

Issue 3
2021 Issue 3
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#